Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.

Nucleic acid therapeutics - 1 Jun 2020

Goel Varun, Gosselin Nathalie H, Jomphe Claudia, Zhang Xiaoping, Marier Jean-Francois, Robbie Gabriel J

Abstract excerpt

Hereditary transthyretin-mediated amyloidosis is an inherited, rapidly progressive, life-threatening disease caused by mutated transthyretin (TTR) protein. Patisiran is a small interfering RNA (siRNA) formulated in a lipid nanoparticle that inhibits hepatic TTR protein synthesis by RNA interference. We have developed an indirect-response pharmacokinetic-pharmacodynamic model relating plasma siRNA (ALN-18328)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Drug Carriers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Models, Statistical

Share to Nanoparticles

Share to Neuroprotective Agents

Share to Prealbumin

Share to RNA, Small Interfering

Source

Identifiers

PMID: 32175804
DOI: 10.1089/nat.2019.0841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.PMID 32175804Read ↗

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated AmyloidosisSemantic proximity Read ↗

Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosisSemantic proximity Read ↗

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated AmyloidosisSemantic proximity Read ↗

Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.Semantic proximity Read ↗

Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisSemantic proximity Read ↗

Update on the clinical utility of an RNA interference-based treatment: focus on PatisiranSemantic proximity Read ↗

APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA.Semantic proximity Read ↗

A quantitative systems pharmacology (QSP) platform for preclinical to clinical translation of in-vivo CRISPR-Cas therapySemantic proximity Read ↗

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatmentsSemantic proximity Read ↗

Real-World Effectiveness and Clinical Predictors of Response to First-Generation TTR Silencers in Variant ATTR Amyloidosis with PolyneuropathySemantic proximity Read ↗

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.